| Lauren Law, DO | |
|
27901 Woodward Ave, Berkley, MI 48072-0919 | |
| (248) 482-2150 | |
| (248) 307-8201 |
| Full Name | Lauren Law |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 8 Years |
| Location | 27901 Woodward Ave, Berkley, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558712752 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 5101022279 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Center For Dermatology And Pathology Pllc | 0446330492 | 43 |
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) of its AnalyST™ implantable cardioverter defibrillator (ICD) with ST Monitoring, a revolutionary device that not only provides life-saving therapy for dangerously fast heart rhythms, but also continuously monitors electrical changes (called ST segments) to help physicians monitor for cardiac problems.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Today, 120 fourth-year medical students at Penn State College of Medicine learned where they will spend their residencies in an annual tradition known as Match Day. A similar scene played out with fourth-year students at medical schools across the country.
› Verified 1 days ago
| Entity Name | Midwest Center For Dermatology & Pathology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003095084 PECOS PAC ID: 0446330492 Enrollment ID: O20080103000679 |
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) of its AnalyST™ implantable cardioverter defibrillator (ICD) with ST Monitoring, a revolutionary device that not only provides life-saving therapy for dangerously fast heart rhythms, but also continuously monitors electrical changes (called ST segments) to help physicians monitor for cardiac problems.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Today, 120 fourth-year medical students at Penn State College of Medicine learned where they will spend their residencies in an annual tradition known as Match Day. A similar scene played out with fourth-year students at medical schools across the country.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Law, DO 27901 Woodward Ave, Berkley, MI 48072-0919 Ph: (248) 482-2150 | Lauren Law, DO 27901 Woodward Ave, Berkley, MI 48072-0919 Ph: (248) 482-2150 |
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) of its AnalyST™ implantable cardioverter defibrillator (ICD) with ST Monitoring, a revolutionary device that not only provides life-saving therapy for dangerously fast heart rhythms, but also continuously monitors electrical changes (called ST segments) to help physicians monitor for cardiac problems.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Today, 120 fourth-year medical students at Penn State College of Medicine learned where they will spend their residencies in an annual tradition known as Match Day. A similar scene played out with fourth-year students at medical schools across the country.
› Verified 1 days ago
Dr. Chethana Chandrupatla Gottam, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 28903 Woodward Ave, Berkley, MI 48072 Phone: 248-581-0333 Fax: 248-876-9144 |